SCHEMBL3963582

SCHEMBL3963582

Nc1nc2nc(Cl)ncc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
NUDT1 P36639 3/20 0.44
TYRO3 Q06418 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
BACE1 P56817 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
PTPN11 Q06124 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CSNK1A1 P48729 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539008 0.79 KDM4E (0.53) KDM4ETYRO3DYRK1BHSD17B10CSNK1A1
SCHEMBL31561546 0.79 ALDH1A1 (0.53) KDM4ENUDT1HTR3EHTR3BHTR3A
SCHEMBL237122 0.79 ALDH1A1 (0.53) KDM4ENUDT1HTR3EHTR3BHTR3A
SCHEMBL369014 0.76 KDM4E (0.50) KDM4ETYRO3DYRK1B
SCHEMBL15718879 0.76 KDM4E (0.50) KDM4ETYRO3DYRK1B
SCHEMBL1551605 0.76 NUDT1 (0.44) KDM4ENUDT1ALDH1A1MEN1KMT2A
SCHEMBL1551962 0.76 KDM4E (0.50) KDM4ETYRO3DYRK1BALDH1A1
SCHEMBL30175417 0.76 ALDH1A1 (0.46) KDM4ENUDT1PTPN11ALDH1A1MEN1
SCHEMBL15571871 0.72 KDM4E (0.46) KDM4ENUDT1TYRO3DYRK1BALDH1A1
SCHEMBL18114688 0.71 KDM4E (0.46) KDM4ETYRO3DYRK1BKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1544434-A 6-benzylaminopurine production process 宝应县润扬化工有限公司 2004-11-10 CN claimed
JP-10218880-A None JP disclosed
JP-6116266-A None JP disclosed
EP-4658280-A2 SIX MEMBERED RING CONTAINING OLIGOMERS Alnylam Pharmaceuticals, Inc. (US) 2025-12-10 EP disclosed
WO-2024163762-A2 SIX MEMBERED RING CONTAINING OLIGOMERS ALNYLAM PHARMACEUTICALS, INC. (US) 2024-08-08 WO disclosed
CN-1592792-B Materials and methods for detection of nucleic acids ERAGEN BIOSCIENCES INC 2010-12-01 CN disclosed
US-7560550-B2 Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives RFS PHARMA, LLC (US) 2009-07-14 US disclosed
WO-2008154286-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-18 WO disclosed
US-20080306076-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-11 US disclosed
US-7189849-B2 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2007-03-13 US disclosed
CN-1592792-A Materials and methods for detection of nucleic acids ERAGEN BIOSCIENCES INC (US) 2005-03-09 CN disclosed
US-20040248910-A1 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2004-12-09 US disclosed
CN-1544434-A 6-benzylaminopurine production process 宝应县润扬化工有限公司 2004-11-10 CN disclosed
US-20040024214-A1 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2004-02-05 US disclosed
US-6613936-B1 Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine MEDIVIR AB (SE) 2003-09-02 US disclosed
EP-1131323-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES Medivir Aktiebolag (SE) 2001-09-12 EP disclosed
US-6184376-B1 POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG MEDIVER AB (SE) 2001-02-06 US disclosed
WO-2000008025-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2000-02-17 WO disclosed
JP-H10218880-A PRODUCTION 2-AMINOPURINE DERIVATIVE SUMIKA FINE CHEM KK 1998-08-18 JP disclosed
JP-H06116266-A PRODUCTION OF 2-AMINO-6-ALKOXYPURINE NIPPON KAYAKU CO LTD 1994-04-26 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306076-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH OR51E2, TAS2R50, TAS2R30 KDM4E 4397/4885NUDT1 3962/4885TYRO3 1293/4885
US-20040024214-A1 Synthesis of acyclic nucleoside derivatives NSUN2, SLC28A1, NUDT1 KDM4E 4410/4885NUDT1 3/4885TYRO3 4390/4885
US-20040248910-A1 Synthesis of acyclic nucleoside derivatives NSUN2, SLC28A1, NUDT1 KDM4E 4410/4885NUDT1 3/4885TYRO3 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.